A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo - Wikidata - awgldk - TriplyDB

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

http://www.wikidata.org/entity/Q27665195

about

Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation The PCSK9 decade PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases Computational design of a symmetric homodimer using -strand assembly Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor Antibody modeling assessment II. Structures and models PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future Genetics of coronary artery disease: an update PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Ancestry and other genetic associations with plasma PCSK9 response to simvastatin.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9 Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 Glucagon receptor antagonism induces increased cholesterol absorption.Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice.Autosomal dominant hypercholesterolemia: needs for early diagnosis and cascade screening in the tunisian population.PCSK9: an emerging target for treatment of hypercholesterolemia.Pharmacological strategies for lowering LDL cholesterol: statins and beyond.Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins.Proprotein convertase subtilisin/kexin type 9: a new target molecule for gene therapy.Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.PCSK9 Inhibitors: potential in cardiovascular therapeutics.Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.The role of genetic risk factors in coronary artery disease.Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?Lipid lowering with PCSK9 inhibitors.Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors.Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention.Lipid Lowering Therapy and Circulating PCSK9 Concentration.Genetics-Current and Future Role in the Prevention and Management of Coronary Artery Disease.The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research.

P2860

Q24294486-05C58FD5-EC61-4FDA-8EDC-594769647D58 Q24615397-7BA800B8-65E5-4AE4-BEBB-A43C73804368 Q24633470-016EA38C-5CB7-4F68-80B7-C26B3604D0F3 Q27003094-E403FE65-F18A-489E-88A9-5A337D421D0A Q27009477-B5936088-F4D7-4268-95CB-630556A90CA2 Q27675994-C6DC74D2-99A3-43B1-8F1E-958989448E3B Q27680601-9EA18516-7341-49E9-B0D3-83B1CDC68CFF Q27689511-76538BEE-4333-4FE9-9860-3E471346D831 Q28083595-52BE0CF7-8C11-4415-8F96-CF8D45988CBB Q33732873-4C563560-5268-4E6A-BEBA-C509F8737C1E Q33904455-BC5EC219-F03A-4D37-8AC8-E665C03BACB5 Q34157965-F2E9A357-8A8C-4D49-A944-B43F4C23612C Q34458693-4AAA8409-E4A1-4B42-B4B7-149FF1C0D264 Q34568486-9E24C1BD-F045-4395-982D-1FE3E026BC38 Q34662589-E993D536-5856-46E0-9194-D5BB3FA09ED2 Q35612555-51ED69A0-F408-47CF-8DD7-55BB03BD626E Q35767551-173E88A1-E0EF-4A62-B762-1EB086D5E8C2 Q35771131-F436CD52-92F7-400A-8A80-0B038F7DA97B Q35879455-5A8068AD-0E9B-4F90-88C3-C174F5CFB11A Q36197864-25936340-DF5F-4760-8190-72CF214DE037 Q36520347-A965F228-463F-4297-831D-6E9C7E1B62B6 Q36634114-C6031BBD-BD5E-487F-A876-85519D51C611 Q37825903-E532E395-78E3-4576-A4B1-7FE5360B5A40 Q37842120-775542FC-E82C-4CF6-B71B-C9E1A1BE7217 Q37972887-B9489D8D-E341-4876-B43A-CD9310ACC7CC Q37981958-F1474C5E-D126-46BD-913F-5711E40C69B9 Q38001736-DAC30E7A-B058-4BE3-988C-B5B4E06CAA90 Q38075818-753765A8-AB29-4758-8A9F-1DD5A9CE5C7C Q38095872-20C67C14-FEC7-4581-925F-DD5EED4C93A8 Q38151675-8CF240F8-1F6B-44B2-A7A3-3AD58E2750FB Q38201295-4DE1DCAC-50C4-4DF6-9EB9-0216FBDCBFDE Q38207925-BA960B80-7886-4A1D-A40E-EF42B83D850F Q38221015-2D53C0BD-69FB-4836-B60F-AE99F0A99CD1 Q38222649-C9DA97E4-EBA5-48D8-A261-2C01580CA363 Q38285812-541CEEC5-2F15-484E-BBF8-8FCB3137F8C7 Q38415736-030A3D82-CA0C-4077-85CD-437847CD26B2 Q38610278-69DE6742-1B87-4E87-90DE-9EB21AB75EB9 Q38643197-14DAA92E-A2A8-4D7D-9083-B351825627A0 Q38798354-31C2772B-7787-408F-B82B-7BA1251F2096 Q38821139-06A09819-6F8F-4440-BF18-8538EDCB512F

P2860

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

http://www.wikidata.org/entity/Q27665195

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A PCSK9-binding antibody that ...... educes LDL cholesterol in vivo

@ast

A PCSK9-binding antibody that ...... educes LDL cholesterol in vivo

@en

A PCSK9-binding antibody that ...... educes LDL cholesterol in vivo

@nl

type

label

A PCSK9-binding antibody that ...... educes LDL cholesterol in vivo

@ast

A PCSK9-binding antibody that ...... educes LDL cholesterol in vivo

@en

A PCSK9-binding antibody that ...... educes LDL cholesterol in vivo

@nl

prefLabel

A PCSK9-binding antibody that ...... educes LDL cholesterol in vivo

@ast

A PCSK9-binding antibody that ...... educes LDL cholesterol in vivo

@en

A PCSK9-binding antibody that ...... educes LDL cholesterol in vivo

@nl

P1433

Q27665195-79309D0E-FE77-4C13-8C00-54CD8C36559C

P1476

Q27665195-2D593445-ADF9-4FA8-BA5E-A6343A25F26D

P2093

Q27665195-0A89B121-9B0E-4F84-B994-D4A338CACAB2

Q27665195-0D272CB2-7EC2-4AA6-A02C-86660491C2DD

Q27665195-2AEAA223-BBD5-433F-AE23-211FAD32578F

Q27665195-31292073-A53D-4FDD-B696-15ABD4C49929

Q27665195-331A4C4B-1D2A-4B40-97A4-C71203C2D108

Q27665195-569E1B0B-3A36-4E61-A8EA-9EFD8D842CD6

Q27665195-618B6663-1E4B-4B00-8B01-CFA2EEAE5745

Q27665195-61DD96D2-6ABE-4C44-BC5F-2EAA4300E044

Q27665195-682A7553-0BA4-4445-81F3-89D058A42621

Q27665195-6DF7F1FA-F59B-4A6D-8643-CC0CEAF10665

P2860

Q27665195-02465B64-293D-4007-BBAF-1D96A68B4A47

Q27665195-02B7B988-6AA8-4DA1-9BC3-322868020C04

Q27665195-04E629F9-8D48-4472-BD0C-A188F3229D15

Q27665195-1546B7D3-0A9C-4564-8F86-4CB5B0B1087D

Q27665195-1B2B795F-E351-4BE6-B89D-C036CCF806E1

Q27665195-1BCF2617-5C92-40BC-96E9-EF300210BAE0

Q27665195-200C2223-384A-4C66-A97F-8C6EB91E005E

Q27665195-21D1D280-3A6F-4781-B6F4-1B01F494FBC4

Q27665195-21E2042D-68D1-4DFE-AA18-BCFEBFD3C4DF

Q27665195-24EB21E8-868B-47E1-B495-9BED805D4F82

P304

Q27665195-7D6C73CF-CFDC-4B8A-8083-B0C1022D280B

P31

Q27665195-0C9F2AA6-8B35-453F-AADE-F52C73FA9F9A

P356

Q27665195-0A4CA01D-11F4-4602-8B76-9813436E09BA

P433

Q27665195-ABDA4D45-0E17-4EAE-9A4C-CF356F564C97

P478

Q27665195-ECE86AB6-EE0F-436D-9198-10686D2DC1DB

P577

Q27665195-8F3EB249-A9AB-4C47-B21C-3D1FC46D9108

P698

Q27665195-270E1766-DC7C-4A57-A72C-E9DAC35436BF

P921

Q27665195-C406BD2F-3451-4988-A6DD-2322B6649AAC

Q27665195-FD6F0242-3931-4D8E-8D2F-CBAC609C124D

P932

Q27665195-DB3E8149-49F6-40E0-9872-102C5CC9FB0E

P356

P1433

Journal of Lipid Research

P1476

A PCSK9-binding antibody that ...... educes LDL cholesterol in vivo

@en

P2093

Andrea Carfí

http://www.w3.org/2001/XMLSchema#string

Ayesha Sitlani

http://www.w3.org/2001/XMLSchema#string

Brian Hubbard

http://www.w3.org/2001/XMLSchema#string

Carl P Sparrow

http://www.w3.org/2001/XMLSchema#string

Cinzia Volpari

http://www.w3.org/2001/XMLSchema#string

Dana D Wood

http://www.w3.org/2001/XMLSchema#string

Douglas G Johns

http://www.w3.org/2001/XMLSchema#string

Douglas Wisniewski

http://www.w3.org/2001/XMLSchema#string

Fubao Wang

http://www.w3.org/2001/XMLSchema#string

Holly A Hammond

http://www.w3.org/2001/XMLSchema#string

P2860

NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants.

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

PROCHECK: a program to check the stereochemical quality of protein structures

Molecular biology of PCSK9: its role in LDL metabolism

Molecular basis for LDL receptor recognition by PCSK9

Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

P304

78-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1194/JLR.M011445

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20959675

http://www.w3.org/2001/XMLSchema#string

P921

P932

2999929

http://www.w3.org/2001/XMLSchema#string